Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Moderna and Pfizer ready updated COVID-19 boosters to combat BA.2.86 and other emerging variants

By Brian Buntz | September 7, 2023

Coronavirus Covid-19 background - 3d rendering

[Image courtesy of Production Perig/Adobe Stock]

Against the backdrop of a nearly 16% spike in COVID-19 hospitalizations in late August, according to CDC data, federal authorities are gearing up to greenlight updated boosters. Moderna announced that its latest COVID vaccine is effective against this new strain. Meanwhile, Pfizer revealed positive preclinical data for its vaccine, developed in collaboration with BioNTech.

In late August, Novavax also announced that its updated protein-based XBB COVID vaccine candidate retained neutralizing antibody responses to several emerging subvariants, including EG.5.1 and XBB.1.16.6. Unlike the mRNA-based boosters from Pfizer and Moderna, Novavax’s COVID vaccine would be the sole protein-based non-mRNA vaccine option available for the upcoming fall season.

The following visualization, based on CDC data, highlights the top SARS-CoV-2 variants for August and September 2023. The BA.2.86 (Pirola) variant, which Moderna and Pfizer highlight as a concern given its potential to break through existing immunity, did not appear among the top 10 for this period. Health authorities have found it in a handful of states.

While the BA.2.86 omicron subvariant possesses a high mutation count, recent findings from the Barouch Lab at Harvard found that neutralizing antibody (NAb) responses to BA.2.86 were lower than to BA.2, an omicron subvariant that surged in 2022. Yet, that response is in line with, or even superior to, reactions to other currently circulating variants.

Compared to related strains, the BA.2.86 variant exhibits over 30 mutations in its spike protein. Experts say BA.2.86 is unlikely to fuel outbreaks in line with the early Omicron waves, according to an article in Nature. Jesse Bloom, a viral evolutionary biologist quoted in that article, posits that such extensive mutations in the spike protein appear to stem from chronic SARS-CoV-2 infections.

COVID vaccines such as Pfizer’s Comirnaty and Moderna’s Spikevax drove huge pharmaceutical revenues in 2022, with Comirnaty topping the best-seller list at $55.92 billion and Spikevax at $18.43 billion.

But the financial outlook for COVID-19 vaccines has shifted as the pandemic progresses. Moderna’s stock has down almost 40% year-to-date, Pfizer’s has fallen 33% and BioNTech has seen a 20% dip over the same period. While Novavax’s stock remains relatively stable this year, its share price has fallen far from its $290-high in early February 2021.


Filed Under: Immunology, Infectious Disease, Regulatory affairs
Tagged With: BA.2.86 variant, biopharma stock trends, COVID-19 vaccines, emerging subvariants, Moderna, Pfizer, pharmaceutical revenues, SARS-CoV-2 variants, vaccine boosters
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE